News
Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback